Demeclocycline treatment in the syndrome of inappropriate antidiuretic hormone secretion.
We have studied the effects of demeclocycline on the water metabolism of a patient with the syndrome of inappropriate antidiuretic hormone (ADH) secretion who presented with a serum sodium concentration of 110 meq/litre. Free water clearance was studied before, during, and after treatment with demeclocycline. This study shows that demeclocycline (900 mg/day) can at least partially inhibit the action of ADH in the setting of tumor-induced ADH secretion, with the production of a reversible, partial nephrogenic diabetes insipidus, and with few or no side effects. Demeclocycline may be useful in the treatment of chronic inappropriate ADH secretion.
D018288:Carcinoma, Small Cell / Q000150:complications; D003707:Demeclocycline / Q000009:adverse effects / Q000627:therapeutic use*; D003919:Diabetes Insipidus / Q000139:chemically induced; D006801:Humans; D007010:Hyponatremia / Q000209:etiology; D007674:Kidney Diseases / Q000139:chemically induced; D008175:Lung Neoplasms / Q000150:complications; D008297:Male; D008875:Middle Aged; D009994:Osmolar Concentration; D013577:Syndrome; D014556:Urine; D014667:Vasopressins / Q000378:metabolism* / Q000494:pharmacology
D014667:Vasopressins; D003707:Demeclocycline